Advancing patient care through molecular diagnostic testing

Interpace Diagnostics develops molecular diagnostic tests. You can be assured that all of the molecular tests we offer are driven by rigorous, validated science.

We power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. The unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis.

Interpace Diagnostic Molecular Tests


ThyGenX® Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier molecular testing that aids in the diagnosis of thyroid nodules by identifying genetic alterations associated with thyroid cancer

I am a physician
I am a patient


PancraGen™ molecular diagnostic testing that determines cancer risk in pancreatic cysts

I am a physician
I am a patient

Looking Toward the Future of Molecular Diagnostics

We constantly explore areas for the future, invest in research and partnerships, seek opportunities to expand our molecular diagnostics capabilities and serve additional unmet needs in molecular diagnostic testing.

Coming soon… BarreGEN™

Barrett’s Esophagus


Molecular diagnostic test to determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus

In the pipeline…

Pancreatobiliary Cancer


Late-stage development of a test to assess pancreatobiliary cancer risk by testing tissue taken from biliary stricture brushings


PancraGen® Clinical Utility Study Published

PARSIPPANY, N.J., Jan. 28, 2016 /PRNewswire/ — Interpace Diagnostics (NASDAQ: IDXG) announced today new analyses of data from a multicenter study of 492 patients have been published online in the journal Diagnostic Pathology.  A link to the study, titled, “Influence of Integrated Molecular Pathology Test Results on Real-World Management Decisions for Patients with Pancreatic Cysts: Analysis of Data from a National Registry Cohort,” can be found here. […]

New Medicare Local Coverage Determination for Molecular Testing of Pancreatic Cysts

PARSIPPANY, N.J., Jan. 20, 2016 /PRNewswire/ — Interpace Diagnostics Group (IDXG: NASDAQ) announced today that its Medicareadministrative carrier (MAC), Novitas Solutions, has issued a new local coverage determination (LCD) for PancraGen™, Interpace’s  test for assessing whether pancreatic cysts are likely malignant or benign, and their degree of biological aggressiveness, including risk for further progression, thus optimizing patient management. […]

Test for Thyroid Nodules Now Available Through LabCorp

PARSIPPANY, N.J., Jan. 12, 2016 /PRNewswire/ -- Interpace Diagnostics (NASDAQ: IDXG) announced today that Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the world's leading health care diagnostics company, will begin offering Interpace's new ThyraMirTM microRNA classifier [...]

View All